[
    [
        {
            "time": "2018-01-03",
            "original_text": "Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stocks",
                    "House",
                    "Dems",
                    "Drug-Pricing",
                    "Probe"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "U.S. lawmaker launches investigation into pharma drug pricing",
            "features": {
                "keywords": [
                    "U.S.",
                    "lawmaker",
                    "investigation",
                    "pharma",
                    "drug",
                    "pricing"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "U.S. lawmaker launches investigation into pharma drug pricing",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Merck or AbbVie: Which Has the More Robust Revenue Trajectory?",
            "features": {
                "keywords": [
                    "Merck",
                    "AbbVie",
                    "Revenue",
                    "Trajectory"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck or AbbVie: Which Has the More Robust Revenue Trajectory?",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "House Democrats launch drug-pricing probe into a dozen major health-care companies",
            "features": {
                "keywords": [
                    "House",
                    "Democrats",
                    "drug-pricing",
                    "probe",
                    "health-care",
                    "companies"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "House Democrats launch drug-pricing probe into a dozen major health-care companies",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Analysts’ Recommendations for AbbVie in January",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommendations",
                    "AbbVie",
                    "January"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for AbbVie in January",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Top Ranked Growth Stocks to Buy for January 14th",
            "features": {
                "keywords": [
                    "Top",
                    "Ranked",
                    "Growth",
                    "Stocks",
                    "Buy",
                    "January",
                    "14th"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Top Ranked Growth Stocks to Buy for January 14th",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Analysts’ Recommendations for Merck & Co. in January",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommendations",
                    "Merck",
                    "&",
                    "Co.",
                    "January"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for Merck & Co. in January",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]